Clarithromycin Versus Azithromycin in Treatment of Mild COVID-19 Infection

Covid19 Clinical Trial

Official title:

Efficacy of Clarithromycin in Comparison to Azithromycin in Treatment of Mild COVID-19 Infection, Randomized Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04622891
• Other study ID #: SVU-MED-CHT019-420860
• Status: Completed
• Phase: N/A
• Start date: April 1, 2020
• Est. completion date: July 30, 2020

Study information

• Verified date: November 2020
• Source: South Valley University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The current study was conducted at Qena Governorate, Egypt, during the period from May 2020, to July 2020. The study included 305 COVID-19 cases diagnosed by PCR, patients were randomly assigned to one of three study limps, Azithromycin 500 mg/24 h for 7 days, Clarithromycin 500 /12 h for 7 days, or a control group with no antibiotics, All three groups received only symptomatic treatment for control of fever and cough

Description:

The current study was conducted at Qena Governorate, Egypt, during the period from May 2020, to July 2020. The study included 305 COVID-19 cases diagnosed by PCR, patients were randomly assigned to one of three study limps, Azithromycin 500 mg/24 h for 7 days, Clarithromycin 500 /12 h for 7 days, or a control group with no antibiotics, All three groups received only symptomatic treatment for control of fever and cough.

All study participants underwent full clinical evaluation including duration of fever, cough, dyspnea, anosmia or GIT symptoms, C-reactive protein (CRP), serum ferritin, D-dimer, Complete blood count (CBC), non-contrast chest computed tomography (CT) which was repeated 2 weeks after the start of treatment.

The Azithromycin group included, 107 patients, mean age 45.8 ±18 years, 73 male and 34 female, the Clarithromycin group included 99 patients mean age 46.1±19 years, 68 males and 31 female, the control group included 99 patients, with mean age 41.1 ± 18 years, 73 male and 28 female.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 300
• Est. completion date: July 30, 2020
• Est. primary completion date: July 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• COVID-19 cases

• Oxygen saturation > 93%

• Age >18 years

Exclusion Criteria:

• Patients <18 years,

• patients with Oxygen saturation < 93%, patients with

• Diabetes mellitus or

• heart failure,

• patients on chemotherapy or immunosuppressive therapy

Related Conditions & MeSH terms

• Covid19
• Infection

Intervention

Drug:
• Clarithromycin 500mg
clarithromycin 500
• Azithromycin
azithromycin group
• Placebo
control group

Locations

Country	Name	City	State
Egypt	south-Vally University faculty of medicine	Qena

Sponsors (1)

Lead Sponsor	Collaborator
South Valley University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	time to fever control	time to complete resolution of fever	15 days
Secondary	PCR conversion	time to PCR conversion from first positive PCR for COVID-19 to negative PCR	15 days